Scarica l'app Stockscreener
16.93
2.08%
-0.36
Dopo l'orario di chiusura:
17.61
0.68
+4.02%
Precedente Chiudi:
$17.29
Aprire:
$17.5
Volume 24 ore:
821.61K
Relative Volume:
0.70
Capitalizzazione di mercato:
$783.25M
Reddito:
$82.71M
Utile/perdita netta:
$-102.24M
Rapporto P/E:
-4.6131
EPS:
-3.67
Flusso di cassa netto:
$-76.57M
1 W Prestazione:
+3.11%
1M Prestazione:
-6.31%
6M Prestazione:
+62.95%
1 anno Prestazione:
+34.37%
Intervallo 1D:
$16.91
$17.64
Intervallo di 1 settimana:
$15.86
$17.64
Portata 52W:
$3.42
$21.71
Urogen Pharma Ltd Stock (URGN) Company Profile
Nome
Urogen Pharma Ltd
Settore
Industria
Telefono
972 9 770 7601
Indirizzo
9 HA'TA'ASIYA ST, RA'ANANA
Confronta URGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
16.93 | 770.30M | 82.71M | -102.24M | -76.57M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2025-06-16 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-05-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-04-16 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-19 | Ripresa | Ladenburg Thalmann | Buy |
| 2024-08-22 | Iniziato | Guggenheim | Buy |
| 2023-02-08 | Downgrade | Jefferies | Buy → Hold |
| 2022-04-27 | Iniziato | Berenberg | Buy |
| 2020-04-16 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-13 | Reiterato | H.C. Wainwright | Buy |
| 2020-01-09 | Iniziato | National Securities | Neutral |
| 2019-05-30 | Iniziato | JP Morgan | Neutral |
| 2019-05-29 | Iniziato | Goldman | Neutral |
| 2019-01-29 | Iniziato | H.C. Wainwright | Buy |
| 2018-11-08 | Ripresa | Jefferies | Buy |
| 2018-04-04 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-01-02 | Iniziato | Ladenburg Thalmann | Buy |
| 2017-11-15 | Reiterato | Oppenheimer | Outperform |
| 2017-11-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
Mostra tutto
Urogen Pharma Ltd Borsa (URGN) Ultime notizie
Tick level data insight on UroGen Pharma Ltd. volatilityWeekly Trend Report & Entry and Exit Point Strategies - newser.com
Using AI based signals to follow UroGen Pharma Ltd.Market Sentiment Review & Comprehensive Market Scan Reports - newser.com
How UroGen Pharma Ltd. stock compares to industry benchmarksTake Profit & Fast Momentum Entry Tips - newser.com
Is UroGen Pharma Ltd. (UR8) stock worth holding before Fed meetingJuly 2025 EndofMonth & Safe Entry Trade Reports - newser.com
Can UroGen Pharma Ltd. stock resist sector downturns2025 EndofYear Setup & Fast Entry High Yield Tips - newser.com
UroGen Pharma Ltd Stock Analysis and ForecastFederal Reserve Announcements & Fast Growing Investment Ideas - earlytimes.in
Is UroGen Pharma Ltd. stock bottoming out2025 Macro Impact & Short-Term High Return Strategies - newser.com
Why UroGen Pharma Ltd. (UR8) stock trades below fair valueTrade Risk Assessment & High Win Rate Trade Alerts - newser.com
Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Cuts Target Price to $36 - 富途牛牛
Bender Robert & Associates Invests $475,000 in Urogen Pharma $URGN - MarketBeat
What technical models suggest about UroGen Pharma Ltd.’s comebackJuly 2025 Market Mood & Momentum Based Trading Ideas - newser.com
Chris Degnan Sells 2,203 Shares of Urogen Pharma (NASDAQ:URGN) Stock - MarketBeat
Understanding UroGen Pharma Ltd.’s price movementEarnings Beat & Safe Swing Trade Setups - newser.com
Is UroGen Pharma Ltd. reversing from oversold territoryJuly 2025 Breakouts & Weekly High Return Opportunities - newser.com
Is UroGen Pharma Ltd. (UR8) stock a momentum leaderJuly 2025 Analyst Calls & High Accuracy Swing Entry Alerts - newser.com
Weiss Ratings Reiterates "Sell (D-)" Rating for Urogen Pharma (NASDAQ:URGN) - MarketBeat
UroGen Pharma CFO Degnan sells $37k in shares By Investing.com - Investing.com South Africa
UroGen Pharma CFO Degnan sells $37k in shares - Investing.com
UroGen continues to climb after bladder cancer drug approval - MSN
UroGen Pharma Ltd.'s (NASDAQ:URGN) Price Is Out Of Tune With Revenues - Sahm
Is UroGen Pharma Ltd a good long term investmentVolatility Index Analysis & Consistent Triple Returns - earlytimes.in
UroGen Pharma Ltd. stock outlook for YEARPortfolio Value Report & Intraday High Probability Setup Alerts - newser.com
How to recover losses in UroGen Pharma Ltd. stock2025 Trading Volume Trends & Fast Moving Market Watchlists - newser.com
Can swing trading help recover from UroGen Pharma Ltd. lossesJobs Report & High Accuracy Swing Entry Alerts - newser.com
NMIBC Market to Experience Notable Growth in Forecast Span - openPR.com
UroGen Pharma (URGN): Maintained Buy Rating by D. Boral Capital | URGN Stock News - GuruFocus
Urogen Pharma (NASDAQ:URGN) Earns "Buy" Rating from D. Boral Capital - MarketBeat
Why UroGen Pharma Ltd. (UR8) stock stays on buy listsMarket Risk Analysis & Scalable Portfolio Growth Methods - newser.com
UroGen’s bladder cancer treatment shows durable response in clinical trials By Investing.com - Investing.com Nigeria
Can machine learning forecast UroGen Pharma Ltd. recoveryAnalyst Downgrade & Weekly Setup with ROI Potential - newser.com
ZUSDURI™ Clinical Review Published in Reviews in Urology™ - GlobeNewswire
Can IL FS Transportation Networks Limited Deliver Margin Expansion Amid InflationEquity Performance Review & Small Investment Portfolio Tips - earlytimes.in
What drives UroGen Pharma Ltd stock priceStock Market Trends & Smart Beta Strategies That Actually Work - earlytimes.in
URGN: UroGen Pharma's ZUSDURI Shows Promising Results for Bladder Cancer - GuruFocus
ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer - The Manila Times
ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer - GlobeNewswire
Urogen Pharma Ltd Azioni (URGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Urogen Pharma Ltd Azioni (URGN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Schoenberg Mark | Chief Medical Officer |
Sep 08 '25 |
Sale |
19.11 |
871 |
16,645 |
149,025 |
| Smith Jason Drew | General Counsel |
Sep 08 '25 |
Sale |
19.11 |
1,520 |
29,047 |
43,305 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):